GlassScriptPhysician profile
Michael L Swank
NPI 1982641999
$563,022.28
in general payments reported to CMS, 2019-2025
11 companies · $96K in 2025
The $96K reported for 2025 was more than what 97% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39K · 2020: $53K · 2021: $44K · 2022: $66K · 2023: $104K · 2024: $161K · 2025: $96K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $350K · Consulting Fee: $7,874 · Travel and Lodging: $1,384 · Food and Beverage: $1,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $350,240.43 |
| Consulting Fee | $7,874.45 |
| Travel and Lodging | $1,384.13 |
| Food and Beverage | $1,049.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $529,999.03 | 2019-2025 | Navio, Real Intelligence |
| Depuy Synthes Products, INC. | $17,479.37 | 2019-2021 | |
| Medical Device Business Services, INC. | $10,995.11 | 2019-2023 | Velys |
| Restor3d, INC. | $3,705.65 | 2025 | |
| Depuy Synthes Sales INC. | $355.33 | 2024-2025 | Monovisc, Orthovisc |
| Baxter Healthcare | $141.15 | 2023-2024 | Perclot, Floseal, Tisseel |
| Orthalign INC | $139.29 | 2025 | Orthalign Plus |
| Heron Therapeutics, INC. | $123.39 | 2024 | Zynrelef |
| Zimmer Biomet Holdings, INC. | $41.69 | 2023-2024 | Persona, Gel-One Cross-Linked Hyaluronate |
| Vertex Pharmaceuticals Incorporated | $26.29 | 2025 | |
| Stryker Corporation | $15.98 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$4,198.90 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Swank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.